Clinical Trials and Research

Swelling and fluid retention are common symptoms for individuals with transthyretin amyloid cardiomyopathy (ATTR-CM). This condition causes the heart muscle to…

In Las Vegas, Nevada, United States, DelveInsight's assessment reveals that globally, there are 10 key companies actively developing treatment therapies for AL…

Impact of disease-modifying therapies on imaging parameters in cardiac amyloidosis: A systematic review and meta-analysis.

Transthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin (TTR) protein falls apart and forms amyloid, a sticky plaque- like…

PurposeAmyloid positron emission tomography (PET) tracers are increasingly used to detect cardiac amyloidosis (CA). 11C-Pittsburgh compound B (PiB) and 1⁸F-…

a study on AL AmyloidosisAmyloidosisOpen-label Phase 1b/2 study with primary objective of this study is to evaluate the safety, tolerability and efficacy of AZD0120…

AbstractPurpose of ReviewCardiac amyloidosis (CA) results from myocardial infiltration by misfolded amyloidogenic proteins and represents a heterogeneous group of…

AbstractBackground and Objectives: Hereditary transthyretin amyloidosis (ATTRv) is a rare disease caused by pathogenic variants in the transthyretin (TTR) gene.…

Isatuximab monotherapy resulted in promising hematologic response rates with a good safety profile among patients with relapsed/refractory (R/R) light chain (AL)…

Light-chain (AL) amyloidosis is a rare systemic disorder characterized by the deposition of misfolded protein aggregates into various organs such as the heart,…